

S4 Table. Characteristics of extra-validation treatment arms

Treatment arm	Induction therapy regimen	Analyzed patients (n)	Duration of Induction therapy (week)	Temporary Maintenance therapy rate ^{a)} (%)	Maintenance therapy regimen	Duration of Maintenance therapy	Observed median PFS (month)	Predicted median PFS (month) (95% CI) ^{b)}	Observed median OS (month)	Predicted median OS (month) (95% CI)
Qvortrup et al. (2010) [16]	Chronomodulated CAPOX	70	24	74	No treatment	Until PD	8.8	7.5 (4.6-10.4)	15.5	22.9 (17.5-28.4)
	CAPOX	69	24	74	No treatment	Until PD	8.9	7.5 (4.7-10.4)	17.6	22.9 (17.5-28.4)
Ducreux et al. (2011) [17]	CAPOX	156	24	74	No treatment	Until PD	8.8	7.5 (5.5-9.5)	19.9	22.9 (19.0-26.8)
	FOLFOX6	150	24	74	No treatment	Until PD	9.3	7.5 (5.5-9.5)	20.5	21.5 (17.6-25.4)
Tournigand et al. (2006) [18]	FOLFOX7	309	12	74	sLV5FU2	12 weeks	8.7	–	21.2	22.8 (18.8-26.8)
Diaz-Rubio et al. (2012) [19]	CAPOX+Bev	241	18	74	Bev	Until PD	9.7	9.0 (7.3-10.8)	20.0	24.0 (20.6-27.3)
Antonuzzo et al. (2015) [20]	CAPOX+Bev	197	24	74	Bev	Until PD	9.7	9.0 (7.2-10.9)	23.2	25.1 (21.6-28.6)
Vaidyanathan et al. (2010) [21]	mFOLFOX6+Bev	67	16	74	sLV5FU2+Bev	Until PD	10.6	11.3 (8.3-14.3)	26.7	24.3 (18.8-29.9)
Tol et al. (2009) [22]	CAPOX+Bev	368	18	74	Cap+Bev	Until PD	10.7	11.3 (9.7-12.9)	20.3	23.7 (20.4-27.0)
Okita et al. (2012) [23]	mFOLFOX6+Bev	50	16	74	sLV5FU2+Bev	16 weeks	12.8	–	30.1	24.3 (18.0-30.7)

Bev, bevacizumab; Cap, capecitabine; CAPOX, capecitabine and oxaliplatin; CI, confidence interval; FOLFOX, infusional fluorouracil, folinic acid, and oxaliplatin; mFOLFOX, modified fluorouracil, folinic acid, and oxaliplatin; OS, overall survival; PD, progressive disease; PFS, progression-free survival; sLV5FU, simplified infusional fluorouracil and folinic acid.

^{a)}The value was assumed from the weighted mean maintenance therapy rate in the original set, ^{b)}Calculated in only treatment arms recommended to continue maintenance therapy until disease progression.

References

1. Andre T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. *Ann Oncol.* 2007;18:77-81.
2. Scalamogna R, Brugnattelli S, Tinelli C, Sagrafa P, Gattoni E, Tronconi MC, et al. UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. *Oncology.* 2007;72:267-73.
3. Chibaudel B, Maindault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. *J Clin Oncol.* 2009;27:5727-33.
4. Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. *J Cancer Res Clin Oncol.* 2009;135:217-26.
5. Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, et al. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. *Cancer Chemother Pharmacol.* 2011;67:1111-7.
6. Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, et al. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. *Am J Clin Oncol.* 2014;37:19-23.
7. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet.* 2015;385:1843-52.
8. Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, et al. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. *Invest New Drugs.* 2015;33:954-62.
9. Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. *BMC Cancer.* 2014;14:883.
10. Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results: a Turkish Oncology Group Trial. *Oncology.* 2013;85:328-35.
11. Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, et al. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. *Invest New Drugs.* 2013;31:1321-9.
12. Hegewisch-Becker S, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. *Lancet Oncol.* 2015;16:1355-69.
13. Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, et al. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). *BMC Cancer.* 2017;17:243.
14. Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. *Ann Oncol.* 2016;27:1074-81.

15. Kosugi C, Koda K, Denda T, Ishibashi K, Ishida H, Seike K et al. VOICE trial: Final results from multicenter phase II study of assessment of clinical efficiency and safety in capecitabine plus intermittent oxaliplatin together with bevacizumab as first-line therapy for patients with advanced colorectal cancer. *J Clin Oncol.* 2018;36(4 Suppl):740.
16. Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. *Ann Oncol.* 2010;21:87-91.
17. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. *Int J Cancer.* 2011;128:682-90.
18. Tournigand C, Cervantes A, Figuer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. *J Clin Oncol.* 2006;24:394-400.
19. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. *Oncologist.* 2012;17:15-25.
20. Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, et al. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. *World J Gastroenterol.* 2015;21:7281-8.
21. Vaidyanathan G, Groman A, Wilding G, Fakih MG. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. *Oncology.* 2010;79:67-71.
22. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med.* 2009;360:563-72.
23. Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, et al. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. *Invest New Drugs.* 2012;30:2026-31.